Waypoint Bio, a NYC-based biotechnology firm offering novel cell therapies for stable tumors, raised $14.5M in Seed funding.
The spherical was led by Hummingbird Ventures with participation from different buyers, together with Recode Ventures and pre-seed lead Fifty Years.
The corporate intends to make use of the funds to additional improve its CAR T-cell therapies with efficacy towards the tumor microenvironment, and later, Treg therapies for autoimmune ailments.
Co-founded by CEO Xinchen Wang and CSO David Phizicky, Waypoint Bio is a biotechnology firm advancint novel cell therapies for stable tumors utilizing its proprietary spatial pooled screening expertise and lab-in-the-loop method. Whereas the corporate is at present targeted on designing novel, stable tumor cell therapies for most cancers, its expertise empowers drug discovery purposes, together with Treg therapies for autoimmune ailments.
The co-founders are joined by a staff of 11 researchers, scientists and engineers, and a various, knowledgeable Scientific Advisory Board, comprised of:
- Melina Claussnitzer, PhD, Broad Institute of Harvard & MIT
- Robbie Majzner, MD, Dana-Farber Most cancers Institute
- Yvonne Chen, PhD, UCLA
- Shantanu Singh, PhD, Broad Institute
- Ron Lennox, D.Phil. MBA, Biotech entrepreneur and investor
FinSMEs
28/06/2024
